Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-FR | Version v5-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2021-12-16 | 2021-12-02 |
| Drug Identification Number | 02266342 | 02266342 |
| Brand name | FLUMAZENIL INJECTION | FLUMAZENIL INJECTION |
| Common or Proper name | Flumazenil Injection 0.1 mg/mL MD Vial 5 mL | Flumazenil Injection 0.1 mg/mL MD Vial 5 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | FLUMAZENIL | FLUMAZENIL |
| Strength(s) | 0.1MG | 0.1MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 5 mL | 5 mL |
| ATC code | V03AB | V03AB |
| ATC description | ALL OTHER THERAPEUTIC PRODUCTS | ALL OTHER THERAPEUTIC PRODUCTS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-12-01 | |
| Actual start date | 2021-12-01 | 2021-12-01 |
| Estimated end date | 2022-02-01 | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Flumazenil Injection 0.1 mg/mL MD Vial 5 mL effective January 1, 2022 until February 1, 2022. The product will remain on 50% allocation for the remainder of December. | On 50% allocation |
| Health Canada comments |